ArticleYonsei medical journal2026
Risk of Retinal Vascular Occlusive Disease According to Type and Low-Density Lipoprotein-Cholesterol Control after Acute Coronary Syndrome.
Article in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeRetinal vascular occlusive disease (RVOD) may occur as a consequence of systemic vascular dysfunction. Although RVOD has been associated with coronary artery disease, its incidence after acute coronary syndrome (ACS) and the influence of lipid control remain unclear. MATERIALS AND
methodsUsing data from the Korean National Health Information Database (2002-2022), we conducted a nationwide retrospective cohort study including 55040 patients with newly diagnosed ACS [unstable angina (UA) or myocardial infarction (MI)] and age- and sex-matched controls. RVOD outcomes included retinal artery occlusion (RAO) and retinal vein occlusion (RVO). Low-density lipoprotein-cholesterol (LDL-C) control was stratified into four categories (excellent, good, suboptimal, poor) based on guideline-recommended targets. Competing risk analysis was performed to estimate adjusted hazard ratios (aHRs).
resultsThe risk of RVOD was higher in both the UA group [aHR=1.67, 95% confidence interval (CI): 1.56-1.79] and MI group (aHR=1.34, 95% CI: 1.15-1.56) compared with controls. Stratified analysis showed elevated risk in older patients (≥65 years) and males. Among LDL-C groups, poor LDL-C control (≥100 mg/dL) was associated with the highest RVOD risk (aHR = 2.27), compared with both the ACS-free control group and the excellent control group (<55 mg/dL).
conclusionACS is independently associated with increased RVOD risk, particularly among patients with UA, older age, and poor LDL-C control. Intensive lipid-lowering therapy and ophthalmologic follow-up may reduce vision-threatening vascular events in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.